TABLE 1.
Summary of general clinical data, demographic data, and types of data associated with cases in the TB Portalsa
| Parameter | No. (%) of cases |
Total no. of cases | |||||
|---|---|---|---|---|---|---|---|
| XDR | Monoresistance | MDR | NR | In progress | PDR | ||
| Total casesb | 294 (22.6) | 43 (3.3) | 682 (52.5) | 172 (13.2) | 84 (6.5) | 24 (1.8) | 1,299 |
| X-ray data exist | 113 (38.4) | 18 (41.9) | 234 (34.3) | 77 (44.8) | 40 (47.6) | 14 (58.3) | 496 |
| CT data exist | 170 (57.8) | 26 (60.5) | 341 (50.0) | 116 (67.4) | 9 (10.7) | 13 (54.2) | 675 |
| Genomic data exist | 97 (33.0) | 14 (32.6) | 278 (40.8) | 62 (36.0) | 13 (15.5) | 7 (29.2) | 471 |
| Outcome | |||||||
| Still on treatment | 163 (55.4) | 12 (27.9) | 320 (46.9) | 5 (2.9) | 66 (78.6) | 8 (33.3) | 574 |
| Completed | 11 (3.7) | 4 (9.3) | 51 (7.5) | 36 (20.9) | 1 (1.2) | 2 (8.3) | 105 |
| Cured | 37 (12.6) | 20 (46.5) | 141 (20.7) | 92 (53.5) | 4 (4.8) | 6 (25.0) | 300 |
| Default | 21 (7.1) | 0 (0.0) | 69 (10.1) | 11 (6.4) | 5 (6.0) | 6 (25.0) | 112 |
| Died | 32 (10.9) | 2 (4.7) | 41 (6.0) | 8 (4.7) | 1 (1.2) | 0 (0.0) | 84 |
| Failure | 12 (4.1) | 0 (0.0) | 28 (4.1) | 4 (2.3) | 0 (0.0) | 2 (8.3) | 46 |
| Unknown | 7 (2.4) | 2 (4.7) | 8 (1.2) | 14 (8.1) | 1 (1.2) | 0 (0.0) | 32 |
| Case definition | |||||||
| Patient has never been treated for TB or has taken anti-TB drugs for <1 mo | 67 (22.8) | 28 (65.1) | 327 (47.9) | 139 (80.8) | 53 (63.1) | 14 (58.3) | 628 |
| Patient has previously been treated for TB | 64 (21.8) | 10 (23.3) | 142 (20.8) | 22 (12.8) | 12 (14.3) | 4 (16.7) | 254 |
| Patient has previously been treated for TB and was declared lost to follow-up at the end of his/her most recent course of treatment | 32 (10.9) | 4 (9.3) | 99 (14.5) | 6 (3.5) | 9 (10.7) | 2 (8.3) | 152 |
| Patient has previously been treated for TB, and treatment failed at the end of his/her most recent course of treatment | 119 (40.5) | 0 (0.0) | 95 (13.9) | 2 (1.2) | 5 (6.0) | 3 (12.5) | 224 |
| Patient has previously been treated for TB, but outcome after his/her most recent course of treatment is unknown or undocumented | 12 (4.1) | 0 (0.0) | 17 (2.5) | 2 (1.2) | 2 (2.4) | 1 (4.2) | 34 |
| Gender | |||||||
| Female | 89 (30.3) | 18 (41.9) | 181 (26.5) | 59 (34.3) | 22 (26.2) | 1 (4.2) | 370 |
| Male | 205 (69.7) | 25 (58.1) | 501 (73.5) | 113 (65.7) | 62 (73.8) | 23 (95.8) | 929 |
| Case origination | |||||||
| Azerbaijan | 16 (5.4) | 4 (9.3) | 102 (15.0) | 25 (14.5) | 2 (2.4) | 1 (4.2) | 150 |
| Belarus | 137 (46.6) | 19 (44.2) | 244 (35.8) | 95 (55.2) | 0 (0.0) | 12 (50.0) | 507 |
| Georgia | 50 (17.0) | 8 (18.6) | 158 (23.2) | 25 (14.5) | 60 (71.4) | 7 (29.2) | 308 |
| Moldova | 53 (18.0) | 5 (11.6) | 101 (14.8) | 18 (10.5) | 14 (16.7) | 4 (16.7) | 195 |
| Romania | 35 (11.9) | 7 (16.3) | 76 (11.1) | 9 (5.2) | 7 (8.3) | 0 (0.0) | 134 |
| Age of onset (yr) | |||||||
| <15 | 0 (0.0) | 1 (2.3) | 4 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 |
| 15–24 | 34 (11.6) | 3 (7.0) | 89 (13.0) | 21 (12.2) | 6 (7.1) | 2 (8.3) | 155 |
| 25–34 | 83 (28.2) | 10 (23.3) | 181 (26.5) | 39 (22.7) | 21 (25.0) | 5 (20.8) | 339 |
| 35–44 | 74 (25.2) | 8 (18.6) | 145 (21.3) | 31 (18.0) | 17 (20.2) | 7 (29.2) | 282 |
| 45–54 | 57 (19.4) | 10 (23.3) | 148 (21.7) | 36 (20.9) | 23 (27.4) | 7 (29.2) | 281 |
| 55–64 | 40 (13.6) | 6 (14.0) | 86 (12.6) | 26 (15.1) | 13 (15.5) | 3 (12.5) | 174 |
| 65+ | 6 (2.0) | 5 (11.6) | 29 (4.3) | 19 (11.0) | 4 (4.8) | 0 (0.0) | 63 |
| Comorbidity(ies) | |||||||
| Liver diseases and other comorbidities | 0 (0.0) | 1 (2.3) | 5 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 |
| Liver diseases | 10 (3.4) | 1 (2.3) | 22 (3.2) | 2 (1.2) | 10 (11.9) | 2 (8.3) | 47 |
| Other comorbidities | 32 (10.9) | 2 (4.7) | 41 (6.0) | 2 (1.2) | 7 (8.3) | 0 (0.0) | 84 |
| Diabetes and HIV/AIDS | 5 (1.7) | 0 (0.0) | 8 (1.2) | 1 (0.6) | 1 (1.2) | 0 (0.0) | 15 |
| Diabetes | 3 (1.0) | 1 (2.3) | 15 (2.2) | 3 (1.7) | 7 (8.3) | 1 (4.2) | 30 |
| HIV/AIDS and other comorbidities, including liver diseases | 5 (1.7) | 0 (0.0) | 8 (1.2) | (0.0) | 2 (2.4) | 0 (0.0) | 15 |
| HIV/AIDS | 13 (4.4) | 1 (2.3) | 25 (3.7) | 1 (0.6) | 0 (0.0) | 1 (4.2) | 41 |
a
Resistance definitions are as follows: monoresistance is resistance to one first-line anti-TB drug only, polydrug resistance (PDR) is resistance to more than one first-line anti-TB drug (other than both isoniazid and rifampin), multidrug resistance (MDR) is resistance to at least both isoniazid and rifampin, and extensive drug resistance (XDR) is resistance to any fluoroquinolone and to at least one of 3 second-line injectable drugs (capreomycin, kanamycin, and amikacin) in addition to multidrug resistance. “In progress” describes cases whose full case data entry is not yet complete. NR, no resistance to TB drugs.
b
Percentage of the total number of cases in the TB Portals (n = 1,299).